Cargando…

High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis

Polymyositis is a rare debilitating condition characterized by chronic inflammation and muscle weakness. Standard treatments include corticosteroids and immunosuppressants; however, resistance to these regimens may develop. Intravenous immunoglobulins (IVIg) are thus recommended for patients with dr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patrick, Cherin, Jean-Christophe, Delain, Jean-Charles, Crave, Odile, Cartry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124644/ https://www.ncbi.nlm.nih.gov/pubmed/25140268 http://dx.doi.org/10.1155/2014/458231

Ejemplares similares

Corrigendum to “High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis”
por: Cherin, Patrick, et al.
Publicado: (2015)

Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases
por: Cherin, Patrick, et al.
Publicado: (2015)

Subcutaneous immunoglobulins for the treatment of a patient with antisynthetase syndrome and secondary chronic immunodeficiency after anti-CD20 treatment: a case report
por: Cherin, Patrick, et al.
Publicado: (2017)

Recovering autonomy is a key advantage of home-based immunoglobulin therapy in patients with myositis: A qualitative research study
por: Chérin, Patrick, et al.
Publicado: (2020)

Subcutaneous Edema in Polymyositis and Dermatomyositis
por: Yoshimi, Ryusuke, et al.
Publicado: (2023)

Contribution of Flexig mobile application to assess adherence of patients treated with immunoglobulins in chronic diseases
por: Pindi Sala, Taylor, et al.
Publicado: (2023)

Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort “Visages”
por: Bienvenu, B., et al.
Publicado: (2016)

In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
por: Cozon, Grégoire Jacques Noël, et al.
Publicado: (2018)

Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients
por: Bienvenu, Boris, et al.
Publicado: (2018)

New Frontiers in Subcutaneous Immunoglobulin Treatment
por: Jolles, Stephen, et al.
Publicado: (2011)

Covariation of MHC class I and CD163 positive macrophages in skeletal muscle tissue of polymyositis and dermatomyositis patients after treatment with high-dose intravenous immunoglobulin (IVIg)
por: Barbasso, S, et al.
Publicado: (2003)

POLYMYOSITIS
Publicado: (1958)

Polymyositis
Publicado: (1899)

Is It Polymyositis?
por: Bansal, Tapesh
Publicado: (2023)

Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy
por: Goyal, Namita A., et al.
Publicado: (2021)

Myasthenic crisis and polymyositis induced by one dose of nivolumab
por: Kimura, Toshihiro, et al.
Publicado: (2016)

Low-dose subcutaneous immunoglobulin is an effective treatment for autoimmune bullous skin disorders: A case report
por: Streu, Erin, et al.
Publicado: (2020)

High-dose immunoglobulin-dependent chronic demyelinating inflammatory polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis
por: Hiya, Satomi, et al.
Publicado: (2022)

Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
por: Dolenc-Voljč, M., et al.
Publicado: (2013)

Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin
por: Kovács, Edina, et al.
Publicado: (2017)

Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis
por: Garnero, Martina, et al.
Publicado: (2018)

Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
por: Gentile, Luca, et al.
Publicado: (2021)

Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study
por: Borte, Michael, et al.
Publicado: (2023)

Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
por: Rosenbach, Kevin, et al.
Publicado: (2023)

Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis
por: Oddis, Chester V., et al.
Publicado: (2022)

Safety, efficiency, and treatment satisfaction in children with primary immunodeficiency receiving subcutaneous immunoglobulin treatment
por: Eltan, Sevgi Bilgic, et al.
Publicado: (2022)

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
por: Skoda-Smith, Suzanne, et al.
Publicado: (2010)

Low dose immunoglobulin g for treatment of severe sepsis and septic shock
por: Iizuka, Y, et al.
Publicado: (2015)

Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis
por: Hirai, Takuya, et al.
Publicado: (2018)

Evaluation and Management of Polymyositis
por: Hunter, Kathy, et al.
Publicado: (2012)

Nutrition and Polymyositis and Dermatomyositis
por: Loell, Ingela, et al.
Publicado: (2008)

The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?
por: Han, Ji Whan
Publicado: (2017)

Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab
por: Knight, Tyler, et al.
Publicado: (2017)

Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease
por: Peshbahar, Soran, et al.
Publicado: (2020)

Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial
por: Miyasaka, Nobuyuki, et al.
Publicado: (2011)

Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy
por: Orange, J S, et al.
Publicado: (2012)

High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects
por: Liu, Xiaosheng, et al.
Publicado: (2020)

Severe polymyositis occurring in a cancer patient directly after chemotherapy: etiology and management
por: Soutif, Charles, et al.
Publicado: (2021)

Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency
por: Sidhu, Jagdev, et al.
Publicado: (2014)

Polymyositis and the Spectrum of Scleroderma Disorders
por: Cochicho, Joana, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_okmjm92qosjotb3djgdo465q4r